Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
Public ClinicalTrials.gov record NCT05478499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.
Study identification
- NCT ID
- NCT05478499
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2022 (Actual)
- Primary completion
- Jan 11, 2024 (Actual)
- Completion
- Oct 17, 2024 (Actual)
- Last update posted
- Oct 28, 2025
2022 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0001 | Hot Springs | Arkansas | 71913 | — |
| Local Institution - 0007 | Indianapolis | Indiana | 46256 | — |
| Local Institution - 0041 | Louisville | Kentucky | 40217 | — |
| Local Institution - 0022 | Rockville | Maryland | 20850 | — |
| Local Institution - 0008 | Beverly | Massachusetts | 01915 | — |
| Local Institution - 0047 | Bloomfield Hills | Michigan | 48302 | — |
| Local Institution - 0002 | New Brighton | Minnesota | 55432 | — |
| Local Institution - 0049 | East Windsor | New Jersey | 08520 | — |
| Local Institution - 0051 | Kew Gardens | New York | 11415 | — |
| Local Institution - 0003 | Portland | Oregon | 97201 | — |
| Local Institution - 0005 | Pittsburgh | Pennsylvania | 15213 | — |
| Local Institution - 0033 | Houston | Texas | 77004 | — |
| Local Institution - 0004 | San Antonio | Texas | 78229 | — |
| Local Institution - 0006 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05478499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2025 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05478499 live on ClinicalTrials.gov.